Sort by

Send to

Choose Destination

Links from PubMed

Items: 3


Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group.

Jacobs S, Fox E, Krailo M, Hartley G, Navid F, Wexler L, Blaney SM, Goodwin A, Goodspeed W, Balis FM, Adamson PC, Widemann BC.

Clin Cancer Res. 2010 Jan 15;16(2):750-4. doi: 10.1158/1078-0432.CCR-09-1906. Epub 2010 Jan 12.


Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.

Steinberg M.

Clin Ther. 2008 Sep;30(9):1590-617. doi: 10.1016/j.clinthera.2008.09.015. Review.


Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.

Rivera E, Lee J, Davies A.

Oncologist. 2008 Dec;13(12):1207-23. doi: 10.1634/theoncologist.2008-0143. Epub 2008 Dec 16. Review.

Supplemental Content

Support Center